慢性丙型肝炎患者干扰素治疗前后黄斑中心凹下脉络膜厚度的研究  

Changes in subfoveal choroidal thickness after interferon therapy in chronic hepatitis C patients

作　　者：毛菲菲[1] 游启生[2] 李丹[1] 孙挥宇[1] 柳月红[1] 刘彬彬[1] 许雪静[1] 董愉[1] 

机构地区：[1]首都医科大学附属北京地坛医院眼科,100015 [2]首都医科大学附属北京同仁医院眼科中心,100102

出　　处：《眼科》2014年第4期240-243,共4页Ophthalmology in China

摘　　要：目的利用相干光断层扫描仪深度增强成像(EDI-OCT)模式分析慢性丙型肝炎干扰素治疗前后脉络膜厚度的变化。设计回顾性病例系列。研究对象北京地坛医院干扰素治疗的平均年龄(43.7±10.5)岁的HCV患者11例(22眼)。方法在接受干扰素治疗前及治疗后3个月行矫正视力、眼压、裂隙灯显微镜、散瞳间接检眼镜、眼底彩色照相及用海德堡SPECTRALIS-OCT深度增强成像模式检查。主要指标黄斑中心凹下脉络膜厚度(SFCT)。结果 11例患者中6例9眼出现干扰素相关性视网膜病变。22眼治疗前SFCT(317.6±78.8)μm和治疗后(280.1±77.1)μm有明显统计学差异(P=0.000)。出现视网膜病变的眼(9眼)与未出现视网膜病变的眼(13眼)干扰素治疗后SFCT分别为(320.5±82.4)μm和(252.1±61.7)μm(P=0.053)。结论慢性丙型肝炎患者干扰素治疗后SFCT有变薄的趋势。Objective To evaluate changes in choroidal thickness as measured by enhanced depth imaging spectral -domain optical coherence tomography （EDI-OCT） after interferon therapy in chronic hepatitis C patients. Design Retrospective case series. Partici- pants 11 cases （22 eyes） of chronic hepatitis C patients （43.7±10.5 year-old） with interferon therapy from Beijing Ditan Hospital. Methods All the patients underwent detailed ocular examinations including corrected visual acuity, intraocular pressure, slit lamp mi- croscope, indirect ophthalmoscope and color fundus photography. The subfoveal choroidal thickness （SFCT） was measured using EDI -OCT at baseline and 3 months after the treatment with interferon. Main Outcome Measures SFCT. Results Among 11 patients, 9 eyes （5.7%） of 6 cases developed interferon-related retinopathy.13 patients had bilateral retinopathy and 11 patients had unilateral retinopathy. SFCT of patients was （317.6±78.8） μm at the baseline and decreased to （280.1±77.1） μm after interferon therapy （P=0.000）. There was no difference in SFCT between with retinopathy group （320.5±82.4） μm and without retinopathy group （252.1±61.7） μm （P= 0.053）. Conclusion There is an overall thinning of the SFCT on EDI OCT after interferon treatment in chronic hepatitis C patients.

关 键 词：光学相干 深度增强成像 脉络膜厚度 干扰素 

分 类 号：R512.63[医药卫生—内科学]